Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease.
- Author:
Daniéla Oliveira MAGRO
1
;
Paulo Gustavo KOTZE
;
Carlos Augusto Real MARTINEZ
;
Michel Gardere CAMARGO
;
Dioze GUADAGNINI
;
Antonio Ramos CALIXTO
;
Ana Carolina Junqueira VASQUES
;
Maria de Lourdes Setsuko AYRIZONO
;
Bruno GELONEZE
;
José Carlos PAREJA
;
Mario José SAAD
;
Claudio Saddy Rodrigues COY
Author Information
- Publication Type:Original Article
- Keywords: Crohn disease; Inflammatory bowel diseases; CD26; Lipopolysaccharides
- MeSH: Biomarkers; C-Reactive Protein; Cell Wall; Crohn Disease*; Enzyme-Linked Immunosorbent Assay; Gram-Negative Bacteria; Humans; Inflammatory Bowel Diseases; Interleukin-17; Interleukin-6; Interleukins; Lipopolysaccharides*; Necrosis; Polysaccharides; Toll-Like Receptor 4
- From:Intestinal Research 2017;15(3):352-357
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Lipopolysaccharide (LPS) is a molecule formed by lipids and polysaccharides and is the major cell wall component of gram-negative bacteria. High LPS levels are known to block CD26 expression by activating Toll-like receptor 4. The aim of this study was to correlate the serum levels of LPS and CD26 in Crohn's disease (CD) patients with serum levels of C-reactive protein (CRP), interleukins, CD activity index, and tumor necrosis factor-α (TNF-α). METHODS: Serum samples were collected from 27 individuals (10 with active CD, 10 with inactive CD, and 7 controls) and the levels of LPS, CD26, TNF-α, interleukin-1β (IL-1β), IL-6, IL-17, and CRP were determined by enzyme-linked immunosorbent assay. The levels of LPS and CD26 were then tested for correlation with TNF-α, IL-1β, IL-6, IL-17, and CRP. RESULTS: Serum levels of LPS were significantly elevated in the active CD group (P=0.003). Levels of IL-1β (P=0.002), IL-6 (P=0.003), and IL-17 (P<0.001) were lower in the CD groups. Serum TNF-α levels were increased in the active CD group. The CRP levels were elevated in the CD groups when compared to controls (P<0.001). The CD26 levels were lower in the CD groups than in the control group (P<0.001). Among the variables analyzed, there was a correlation between LPS and CRP (r=−0.53, P=0.016) in the CD groups. CONCLUSIONS: Individuals with CD exhibited higher serum levels of LPS varying from a 2- to 6-fold increase depending on disease activity, when compared with healthy controls. CD26 levels were lower in the CD groups. Both LPS and CD26 correlated with disease severity and serve as potential CD biomarkers.
